← Back to Screener
Pulmonx Corporation Common Stock (LUNG)
Price$1.42
Favorite Metrics
Price vs S&P 500 (26W)-15.71%
Price vs S&P 500 (4W)-1.41%
Market Capitalization$62.09M
All Metrics
Book Value / Share (Quarterly)$1.30
P/TBV (Annual)3.12x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)19.03%
Cash Flow / Share (Quarterly)$-0.79
Price vs S&P 500 (YTD)-37.62%
Gross Margin (TTM)74.19%
Net Profit Margin (TTM)-59.67%
EPS (TTM)$-1.33
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$-1.33
Revenue Growth (5Y)22.56%
EPS (Annual)$-1.33
ROI (Annual)-59.21%
Gross Margin (Annual)74.19%
Net Profit Margin (5Y Avg)-85.17%
Cash / Share (Quarterly)$1.67
Revenue Growth QoQ (YoY)-4.91%
ROA (Last FY)-41.77%
Revenue Growth TTM (YoY)8.01%
EBITD / Share (TTM)$-1.29
ROE (5Y Avg)-56.08%
Operating Margin (TTM)-59.30%
Cash Flow / Share (Annual)$-0.79
P/B Ratio1.15x
P/B Ratio (Quarterly)1.68x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.33x
Net Interest Coverage (TTM)-45.91x
ROA (TTM)-38.20%
EPS Incl Extra (Annual)$-1.33
Current Ratio (Annual)5.07x
Quick Ratio (Quarterly)4.15x
3-Month Avg Trading Volume0.55M
52-Week Price Return-69.31%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.16
P/S Ratio (Annual)0.69x
Asset Turnover (Annual)0.70x
52-Week High$5.46
Operating Margin (5Y Avg)-85.07%
EPS Excl Extra (Annual)$-1.33
CapEx CAGR (5Y)-13.06%
26-Week Price Return-6.96%
Quick Ratio (Annual)4.15x
13-Week Price Return-26.50%
Total Debt / Equity (Annual)0.69x
Current Ratio (Quarterly)5.07x
Enterprise Value$29.433
Revenue / Share Growth (5Y)19.39%
Asset Turnover (TTM)0.64x
Book Value / Share Growth (5Y)-27.16%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.43x
Pretax Margin (Annual)-58.98%
Cash / Share (Annual)$1.67
3-Month Return Std Dev85.69%
Gross Margin (5Y Avg)74.00%
Net Income / Employee (TTM)$-0
ROE (Last FY)-99.79%
Net Interest Coverage (Annual)-105.76x
EPS Basic Excl Extra (Annual)$-1.33
Receivables Turnover (TTM)7.18x
Total Debt / Equity (Quarterly)0.69x
EPS Incl Extra (TTM)$-1.33
Receivables Turnover (Annual)7.18x
ROI (TTM)-52.76%
P/S Ratio (TTM)0.69x
Pretax Margin (5Y Avg)-84.48%
Revenue / Share (Annual)$2.22
Tangible BV / Share (Annual)$2.16
Price vs S&P 500 (52W)-104.41%
Year-to-Date Return-33.48%
5-Day Price Return2.08%
EPS Normalized (Annual)$-1.33
ROA (5Y Avg)-32.35%
Net Profit Margin (Annual)-59.67%
Month-to-Date Return13.95%
Cash Flow / Share (TTM)$-1.58
EBITD / Share (Annual)$-1.29
Operating Margin (Annual)-59.30%
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-40.34%
LT Debt / Equity (Quarterly)0.68x
EPS Basic Excl Extra (TTM)$-1.33
P/TBV (Quarterly)3.12x
P/B Ratio (Annual)1.68x
Inventory Turnover (TTM)1.43x
Pretax Margin (TTM)-58.98%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)-29.37%
Beta0.26x
Revenue / Share (TTM)$2.19
ROE (TTM)-82.79%
52-Week Low$1.13
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
LUNGPulmonx Corporation Common Stock | 0.69x | 22.56% | 74.19% | -59.30% | $1.42 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Pulmonx develops minimally invasive treatments for severe emphysema and COPD, with its flagship Zephyr Endobronchial Valve supported by diagnostic assessment platforms. The company sells its medical devices to hospitals and distributors across the U.S., Europe, Middle East, Africa, and Asia Pacific. Pulmonx serves patients with limited treatment options in a significant respiratory disease market.